AXSM - Axsome Therapeutics Inc
IEX Last Trade
88.73
-0.380 -0.428%
Share volume: 311,826
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$89.11
-0.38
-0.43%
Fundamental analysis
29%
Profitability
25%
Dept financing
19%
Liquidity
75%
Performance
25%
Performance
5 Days
0.99%
1 Month
4.54%
3 Months
19.74%
6 Months
7.12%
1 Year
11.55%
2 Year
45.10%
Key data
Stock price
$88.73
DAY RANGE
N/A - $90.29
52 WEEK RANGE
$55.02 - $98.40
52 WEEK CHANGE
$0.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Herriot Tabuteau
Region: US
Website: http://axsome.com/
Employees: 353
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://axsome.com/
Employees: 353
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
Recent news